Waters acquires MOBILion Systems’ ion mobility technology

Higher-resolution molecular separation

Waters announced on November 3 that it had acquired MOBILion Systems. MOBILion developed SLIM, or Structures for Lossless Ion Manipulations technology. It provides high-resolution ion mobility separation, separating molecules by their size, shape and charge on a millisecond timescale.

Waters said SLIM complements its mass spectrometry platform, including the speed and resolution of the Xevo MRT MS. The combination is expected to improve proteome coverage, sensitivity and throughput for complex biological samples. Waters believes the solution could deliver greater separation performance in the so-called bottom-up analysis of complex proteomes than liquid chromatography and mass spectrometry used on their own.

Proteomics data for AI models

The acquisition also accelerates Waters’ strategy to enter the proteomics market. Based on the company’s internal analyses and estimates, as well as consultant data, industry reports and market research, the total addressable market for liquid chromatography-mass spectrometry proteomics is $2 billion and is growing at a high-single-digit rate.

Waters said SLIM-based technology could support large-cohort studies and high-throughput, high-quality data generation. The company considers this data necessary for research into foundation models and advanced AI models.

The announcement also highlights Waters AI Link, which brings Anthropic’s Model Context Protocol to the waters_connect software. Waters is also participating in Anthropic’s Model Hardware Standard research program. The company said these capabilities could enable laboratory-contained experiments in which AI agents help design experiments and independently control instrument operation.

Udit Batra, president and CEO of Waters, said the acquisition gives the company a unique advantage in proteomics. He said SLIM ion mobility separation, combined with the speed, resolution and sensitivity of Waters’ mass spectrometry portfolio, could help scientists better understand complex biology and generate the volume of data required by AI foundation and advanced models.

From biomarker discovery to clinical applications

According to Waters, the deal could open a path from biomarker discovery to targeted testing and validation. The Xevo TQ Absolute XR tandem quadrupole mass spectrometer plays a role in this process, and the company describes it as a highly sensitive and robust system. Workflows on the waters_connect platform support the transfer of methods from discovery to development, allowing the company to use a single platform to further investigate biomarker candidates and validate them in clinical trial cohorts.

Over the longer term, Waters also sees opportunities to expand blood-based diagnostic applications. Building on its installed base of mass spectrometers in clinical laboratories, the company could translate validated protein biomarkers into routine blood tests. According to the announcement, this could support multiplex diagnostic workflows, such as the early detection of multiple cancer types and monitoring of minimal residual disease.

Melissa Sherman, CEO of MOBILion, said SLIM was designed to observe separations that other methods may not reveal. The financial terms were not disclosed. Waters said MOBILion’s team and ion mobility expertise would join the company through the acquisition, allowing the technology to move from research laboratories toward routine testing over time, according to the announcement.